“Welcome to Lake Wobegon, where all the women are strong, all the men are good-looking, and all the children are above average” – Garrison Keillor
Prostate cancer screening and its detection and subsequent management has been fraught with lots of controversies, mainly because more men die with prostate cancer, rather than from it.
The original statement, often cited as the “Whitmore Principle,” was famously phrased by Willet Whitmore as: “For a patient with prostate cancer, if treatment for cure is necessary, is it possible? If possible, is it necessary?” Fortunately, most men die with prostate cancer, not of it.
This highlights a key characteristic of prostate cancer: it often progresses very slowly due to its long sojourn time. Many men, particularly older individuals, have cancerous cells in their prostate but die from other causes (such as heart disease or old age) before the cancer becomes aggressive enough to be fatal.
The other important characteristic of prostate cancer is that prostate cancer is often described as a “poster boy” example of a scrutiny-dependent cancer, where observed incidence rates are highly influenced by the intensity of screening and detection practices. The more one screens for prostate cancer, the more cancers will be detected and included in the cancer registry.
This distinguishes between a diagnosis of prostate cancer and the actual necessity of immediate, aggressive treatment. It underscores the challenges in determining which cancers are life-threatening from that which are slow-growing or indolent.
Ultimately, prostate cancer highlights the challenges in balancing early detection, which can be life-saving for aggressive cases, with the risks of unnecessary interventions for non-aggressive forms of the disease. This is currently the holy grail of prostate cancer research.
To understand this, one needs to understand the characteristics of prostate cancer, the statistical artifact of stage migration and the above-average effect of illusory superiority.
The characteristics of prostate cancer are:
1. Prostate cancer is a scrutiny-dependent cancer. The more one screens and diagnoses, the more cases will be detected. But this does not mean that early detection will improve cancer-specific mortality.
2. Prostate cancer has a long mean sojourn time, meaning it often exists in a slow, asymptomatic pre-clinical phase for many years (often a decade or more) before it’s detectable by symptoms or routine screening, allowing for early detection but also raising concerns about overdiagnosis and overtreatment of slow-growing cancers that might never harm a man, even if found early.
3. Efficacy vs effectiveness
Although these words – efficacy and effectiveness – appear to describe similar concepts, an understanding of their distinct meanings will help clarify the basis of the differing conclusions about whether PSA screening reduces prostate cancer mortality.
A clinical trial that evaluates the efficacy of PSA screening tests whether PSA screening can lower prostate cancer mortality when compared with no screening in a clinical trial setting under highly controlled and ideal circumstances, such as in a randomized controlled trial.
A clinical trial that evaluates the effectiveness of PSA screening tests whether PSA screening can lower prostate cancer mortality in routine, real-world clinical practice, with a more varied patient population and less standardized condition
PSA screening must be efficacious if it is to be effective, but it may be not effective even when it is efficacious.
Most prostate cancer trials, especially early-phase (I/II) and foundational Phase III studies, focus on efficacy (does it work in ideal conditions?), showing biological effects (PSA changes, T-cell response) or survival benefits (Overall Survival, Cancer Specific Survivals) in controlled settings, but later-stage (Phase IV) and comparative trials increasingly look at effectiveness (does it work in real-world practice?) through patient-reported outcomes, subgroup analysis, and broader population impact, acknowledging that efficacy doesn’t always equal real-world benefit.
In the context of the PSA test for prostate cancer screening:
The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated the efficacy of PSA testing to lower prostate cancer mortality under trial conditions.
However, the ongoing debate and lack of universal recommendation for population-wide PSA screening stem from its questionable effectiveness in a general population due to issues like over-diagnosis and overtreatment, which expose men to potential complications from unnecessary treatment.
For the PSA test to be widely considered an effective public health screening tool, its proven efficacy must translate into a clear, favorable risk-benefit profile when applied in daily practice, which has been a subject of significant controversy
4. Statistical artefacts and cognitive bias – The Will Rogers Effect with the statistical phenomenon of the “above-average effect”, and the Lake Wobegon Effect on illusory superiority.
The Will Rogers Effect:
This term was coined by Feinstein et al.
According to Will Rogers: When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states. This is actually a statistical artifact.
The Will Rogers effect is a statistical phenomenon where the average value of a population can appear to increase, even for the “above average” group, when individuals are reclassified between groups without any actual change in their individual values.
This counterintuitive effect occurs under specific conditions:
1. An element (individual or data point) must be moved from a group with a higher average to a group with a lower average.
2. The value of the element being moved must be below the average of its original (higher-average) group but above the average of its destination (lower-average) group.
The most notable application is in medicine, specifically in cancer treatment statistics, where it is called stage migration. This occurs due to:
1. Improved diagnostic techniques (like advanced imaging) detect cancer earlier or identify smaller metastases.
2. Patients who would previously have been classified in a less severe stage are reclassified into a more severe stage.
3. These reclassified patients have a better prognosis (they are “healthier”) than the existing patients in the severe group, so they raise that group’s average survival rate.
4. At the same time, the remaining patients in the less severe group are those with genuinely better prognoses, so their average survival rate also increases.
The result is an illusion of improved survival rates in both stages, even if no actual medical treatment has improved the outcome for any individual patient. Hence proving that screening alone was not responsible this stage migration.
The Lake Wobegon Effect
The Lake Wobegon effect is a cognitive bias where people overestimate their own abilities and see themselves as better than the average person, a tendency also known as illusory superiority.
Lake Wobegon is a fictional, idyllic small town in central Minnesota, created by humorist Garrison Keillor. He is famous for his phrase “Welcome to Lake Wobegon – where all the women are strong, all the men are good-looking, and all the children are above average.”
It is a systematic bias where over-estimation or over-diagnosis inflates the perceived performance.
The Lake Wobegon Effect in cancer stems from human bias, describes how both patients and doctors tend to be overly optimistic about cancer outcomes, with doctors often framing elderly or terminally ill patients as “above average” and likely to beat the odds, leading patients to overestimate treatment success and delay realistic end-of-life planning, resulting in poor-quality deaths and significant healthcare costs. And thus creating a bias towards aggressive intervention.
The effect manifests in in overtreatment of low-risk disease:
Patient Overestimation of Prognosis:
Patients with low-risk, slow-growing prostate cancer often overestimate their personal risk of dying from the disease, believing they are “above average” compared to statistical data on similar patients. This perception of being uniquely threatened by the cancer, combined with a feeling of being an “above-average” survivor candidate, drives them to choose curative treatments like radical prostatectomy (surgery) or radiation therapy (external beam or brachytherapy). They choose aggressive treatment over the safer, less-invasive option of Active Surveillance (AS), even when AS is clinically appropriate and carries a lower risk of side effects like incontinence and erectile dysfunction.
Physician Overoptimism:
Some evidence suggests that physicians may also be susceptible, unintentionally conveying overly optimistic treatment advice or survival predictions to patients, reinforcing the patient’s illusion of superiority. This automatic optimism can prompt patients to choose treatments that are aggressive and debilitating, especially in older patients where the chance of dying with the cancer (from other causes) is high, rather than from the cancer.
Standard treatment for localised prostate cancer
The standard treatment for localized prostate cancer are active surveillance (for low risk and some intermediate risk cancers), radical prostatectomy (surgical removal of prostate) and External Beam Radiotherapy (EBRT). Currently various focal therapy options have been investigated in the low risk and some intermediate risk categories (example HIFU).
The central issue is the misalignment between perceived benefit and actual risk. Prostate cancer is often indolent (slow-growing), meaning aggressive treatment for low-risk disease provides minimal, if any, survival benefit, but immediately exposes the patient to serious quality-of-life-diminishing side effects. The Lake Wobegon effect makes patients less likely to accept the “doing nothing” approach of Active Surveillance and more likely to insist on a physical intervention.
The Lake Wobegon effect in prostate cancer is a bias where patients believe their prognosis is better than average, often leading them to choose aggressive treatment (like surgery or radiation) for low-risk disease, despite the risk of side effects, rather than safer Active Surveillance.
The Lake Wobegon effect, or “illusory superiority,” impacts PSA screening by leading patients to overestimate the test’s benefits (like believing it saves more lives than current evidence suggests) and underestimate the risks of overdiagnosis and subsequent unnecessary treatment for non-lethal cancers detected by the PSA test.
The Will Rogers and Lake Wobegon Effects create a statistical milieu in modern prostate cancer where outcomes are artificially improved. This environment makes new, minimally invasive therapies like HIFU appear very effective in the short-to-medium term.
Active surveillance:
Active surveillance cohorts show exceptionally high 10-15 year cancer-specific survival rates (often more than 98%). The Lake Wobegon Effect is the primary reason for this. The strategy is brilliantly successful precisely because a large proportion of the men enrolled have “cancer” that doesn’t need treating. This validates AS but also makes it difficult to identify the minority who will progress.
Influence on Practice: The stellar statistics of Active Surveillance become the benchmark. Any new therapy (like focal therapy) for low-risk disease must contend with the fact that it is competing against a “treatment” (Active Surveillance) whose outcomes are artificially superb due to case selection.
Focal therapy: HIFU (High-Intensity Focused Ultrasound):
HIFU is focal therapy for low risk and some intermediate risk prostate cancers, where the prostate is left behind. The argument that HIFU’s effectiveness is similar to Active Surveillance is statistically plausible, as the Lake Wobegon Effect dominates. The key decision hinges on patient preference regarding risk tolerance, anxiety, and quality of life, as a mortality benefit from HIFU over Active Surveillance is highly unlikely to be proven.
The Will Rogers Effect (better staging) and the Lake Wobegon Effect (over-diagnosis) often work together. Better diagnostics (MRI) migrate patients more accurately (Will Rogers), but within a population already inflated with indolent disease (Lake Wobegon). This makes modern outcomes seem dramatically better, complicating the true assessment of new focal treatments like HIFU.
For low-risk and some intermediate risk prostate cancer, current evidence suggests there is no significant difference in disease-specific mortality between patients undergoing High-Intensity Focused Ultrasound (HIFU) and those on active surveillance (AS). Both approaches aim to manage localized cancer with minimal impact on overall survival.
In essence: HIFU is a promising technology that addresses the overtreatment problem by offering a middle path. However, its adoption has, in a sense, outpaced the highest level of evidence.
Its role must be understood within the statistical illusions of modern diagnosis, and it should be offered with the explicit caveat that its ultimate long-term survival outcomes, particularly when stacked against the benchmarks of surgery or radiation, are still being defined.
The ideal candidate is a well-informed man with a significant, image-visible lesion within a specific risk category, for whom preserving quality of life is a paramount concern, and who accepts the current uncertainties in the long-term data.
On Radical Prostatectomy & Radiotherapy:
The oncologic outcomes for surgery and radiation – particularly for low and favorable intermediate-risk disease – appear outstanding. Cancer-specific survival rates are very high. However, a significant portion of this “success” is attributable to operating on or irradiating cancers that posed no mortal threat. This inflates the perceived benefit of the intervention.
The Problem of Over-treatment: This is the most pernicious consequence. The excellent overall statistics, fueled by Lake Wobegon, can mask the true risk-benefit ratio for an individual. A man may accept the risks of incontinence and impotence (from Radical Prostatectomy) or bowel/urinary side effects (from Radiotherapy) believing he has significantly reduced his risk of death, when in fact his risk of dying from that specific cancer was minimal to begin with. The effect thus perpetuates overtreatment by making radical interventions look more broadly necessary than they are.
The Will Rogers and Lake Wobegon effects operate in concert, creating a powerful and sometimes misleading narrative about prostate cancer management.
1. The Foundation of Over-diagnosis (Lake Wobegon): PSA screening creates a large pool of non-lethal cancers. This makes Active Surveillance both necessary (to avoid overtreatment) and statistically brilliant.
2. The Refinement of Categories (Will Rogers): Advanced diagnostics (MRI, genomics) then sort this large pool more accurately. They identify the “worrisome” minorities within low-risk disease (pushing them toward treatment) and the “less aggressive” components within high-risk disease (potentially enabling de-escalation).
3. The Net Effect on Treatment Paradigms:
For Low-Risk Disease: The combined effects have solidified Active Surveillance as the undisputed standard of care. The Lake Wobegon Effect shows most will do fine; the Will Rogers Effect ensures those enrolled are the safest candidates.
For Intermediate-Risk Disease: This is the zone of greatest controversy and decision-making. The Will Rogers Effect has created a “favorable intermediate” sub-category. For these patients, Active Surveillance is increasingly being studied and offered, influenced by the knowledge that some have been “migrated up” from a low-risk biology. For “unfavorable intermediate,” the purified cohort makes the proven benefits of Radical Prostatectomy or Radiotherapy clearer, as we are now treating a more consistently consequential disease.
For High-Risk Disease: Will Rogers migration has pulled the most aggressive cases into this group from intermediate, and pushed the least aggressive out. This means modern High-Risk cohorts in studies have a worse average prognosis than in the past, making it harder to show improved outcomes from new therapies, even if they are genuinely better. It also intensifies the argument for multimodal therapy (surgery + radiation + hormones).
Conclusion for the Clinician and Patient:
Understanding these effects is crucial for informed decision-making.
These explain:
Historical survival data cannot be directly compared to modern data.
A patient diagnosed today has a better “projected outcome” than one with the same Gleason score 20 years ago (partly due to better treatment, but significantly due to better classification).
Why the choice between Active Surveillance, Radical Prostatectomy and Radiotherapy is now more nuanced than ever. The decision must be based on modern, precisely defined risk stratification (which incorporates MRI and sometimes genomics) and a clear-eyed view that the stellar population-level statistics for any option are shaped by these invisible epidemiological forces.
In essence, the Lake Wobegon Effect created the modern problem of prostate cancer management (over-diagnosis), and the Will Rogers Effect is the tool we are using to try and solve it (precision risk stratification).
Together, they have refined our strategies, favoring surveillance for the lowest risk prostate cancers and clarifying the need for radical treatment for the highest risks, while leaving the large middle ground in a state of increasingly personalized evaluation and informed decisions with the patient based on the risk-benefit ratio and their expectations.
